Obesity is considered a chronic inflammatory state characterised by continued secretion of adipokines and cytokines. Experimental and epidemiological evidence indicates that circulating adipokines may be associated with the development of obesity-related cancers, but it is unclear if these associations are causal or confounded. We examined potential causal associations of specific adipokines [adiponectin, leptin, soluble leptin receptor (sOB-R), and plasminogen activator inhibitor-1 (PAI-1)] with five obesity-related cancers (colorectal, pancreatic, renal cell carcinoma, ovarian, and endometrial) using Mendelian randomization (MR) methods. We used summary-level data from large genetic consortia for 114 530 cancer cases and 245 284 controls. We constructed genetic instruments using 18 genetic variants for adiponectin, 2 for leptin, and 4 for both sOB-R and PAI-1 (P-value for inclusion<5 10 ). Causal estimates were obtained using two-sample MR methods. In the inverse-variance weighted models, we found an inverse association between adiponectin and risk of colorectal cancer [odds ratio (OR) per 1 μg/mL increment in adiponectin concentration: 0.90 (95% confidence interval [CI]: 0.84-0.97); P: 0.01]; but, evidence of horizontal pleiotropy was detected and the association was not present when this was taken into consideration. No association was found for adiponectin and risks of pancreatic cancer, renal cell carcinoma, ovarian cancer, and endometrial cancer. Leptin, sOB-R and PAI-1 were also similarly unrelated to risk of obesity-related cancers. Despite the large sample size, our MR analyses do not support causal effects of circulating adiponectin, leptin, sOB-R, and PAI-1 concentrations on the development of five obesity-related cancers. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.